Coeptis Therapeutics Holdings, Inc. Update: Z Squared Merger and Dividend News

If you follow Coeptis Therapeutics, there is a major update regarding the company’s structure and focus. The company has officially transitioned into a new business model as Z Squared, Inc. (ticker: ZSQR). Here is what this means for your investment.

1. What happened?

On April 27, 2026, Z Squared, Inc. confirmed two major changes:

• The Business Combination: The company has pivoted from biopharmaceuticals to become a "computing infrastructure" company. This marks a fundamental shift in its assets and operations.
• The Dividend Distribution: If you held shares on January 2, 2026, you are receiving a dividend. This consists of one share of the legacy biopharmaceutical business—now called Coeptis Holdings, Inc.—for every ZSQR share you owned. Note: These new shares are "non-transferable." They are not listed on any public exchange and you cannot trade them. The company hasn't provided much detail on the future liquidity of these shares, so for now, consider them a long-term, illiquid holding.

2. What is Z Squared now?

Z Squared, Inc. now operates as a data center manager. The company has left the drug development space to manage large-scale computing hardware in North Carolina, South Carolina, and Iowa. Their business model focuses on:

• Infrastructure Management: Maintaining high-density computing hardware.
• Operational Efficiency: Using real-time data to lower power costs and keep systems running profitably.

3. Why does this matter?

This "corporate makeover" splits the company’s assets into two distinct parts:

• The New Entity (ZSQR): This is now a technology company focused on computing power. Its profit depends on data center efficiency and the costs of power and hardware.
• The Old Entity (Coeptis Holdings): This company keeps the original medical research and intellectual property.

This is a critical distinction. The company you now own (ZSQR) is fundamentally different from the biopharmaceutical firm you originally bought. Your investment strategy must shift from tracking clinical trials to analyzing the economics of computing infrastructure.

4. Who is affected?

• Shareholders: If you held stock on January 2, 2026, you now hold two assets: your tradable ZSQR shares and your non-transferable shares in the legacy biopharma business.
• The Market: ZSQR began trading under its new identity on April 27, 2026. Expect price swings as the market adjusts to the company’s new focus on technology rather than biotechnology.

5. What should you do?

• Check your brokerage account: If you were a shareholder on January 2, confirm you received your Coeptis Holdings, Inc. shares. Because these are non-transferable, they will not show a market price or a "sell" button.
• Understand the new business: If you hold ZSQR, ensure your strategy fits the risks of the computing industry. These include fluctuating energy costs and the rapid pace at which hardware becomes outdated.
• Stay informed: Check the Z Squared website to monitor their plans for scaling computing power and managing their assets.

Final Thought for Investors: Before deciding to hold or sell ZSQR, ask yourself if you are comfortable with the risks of the data center industry. Since the company has completely changed its core business, your original reasons for investing in a biopharma firm likely no longer apply. Review the company's latest filings to see if their new tech-focused strategy aligns with your personal portfolio goals.

Disclaimer: I am an AI, not a financial advisor. This summary is for informational purposes only and is not professional investment advice. Always do your own research before trading.